Adipokines, metabolic dysfunction and illness course in bipolar disorder

Journal of Psychiatric Research

Volumn 74, Issue , 2016, Pages 63-69

  Mansur, Rodrigo B ^a,b   Rizzo, Lucas B ^a,c   Santos, Camila M ^a   Asevedo, Elson ^a   Cunha, Graccielle R ^a   Noto, Mariane N ^a,d   Pedrini, Mariana ^a   Zeni, Maiara ^a   Cordeiro, Quirino ^e   McIntyre, Roger S ^b   Brietzke, Elisa ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d Vila Maria Outpatient Clinic   (Brazil)

^e IRMANDADE DA SANTA CASA DE MISERICÓRDIA DE SÃO PAULO   (Brazil)

Author keywords

Adiponectin; Bipolar disorder; Leptin; Metabolism

Indexed keywords

ADIPOCYTOKINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIOBESITY AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; C PEPTIDE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LEPTIN; LITHIUM; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; ADIPONECTIN; ADIPOQ PROTEIN, HUMAN;

ADULT; AGE; ANTHROPOMETRIC PARAMETERS; ARTICLE; BIPOLAR DISORDER; BODY MASS; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FUNCTIONAL STATUS; GLUCOSE BLOOD LEVEL; HOMEOSTATIC MODEL ASSESSMENT INSULIN RESISTANCE; HOSPITALIZATION; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METABOLIC PARAMETERS; MOOD CHANGE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; SEX; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; PATHOPHYSIOLOGY;

ADIPONECTIN; ADULT; BIPOLAR DISORDER; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LEPTIN; MALE; MIDDLE AGED; OBESITY;

EID: 84958078619     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2015.12.003     Document Type: Article

References (71)

1. Arnoldussen I.A., Kiliaan A.J., Gustafson D.R. Obesity and dementia: adipokines interact with the brain. Eur. Neuropsychopharmacol. 2014, 24:1982-1999.
2. Atmaca M., Kuloglu M., Tezcan E., Ustundag B. Weight gain and serum leptin levels in patients on lithium treatment. Neuropsychobiology 2002, 46:67-69.
3. Atmaca M., Kuloglu M., Tezcan E., Ustundag B., Bayik Y. Serum leptin and cholesterol levels in patients with bipolar disorder. Neuropsychobiology 2002, 46:176-179.
4. Barbosa I.G., Rocha N.P., de Miranda A.S., Magalhaes P.V., Huguet R.B., de Souza L.P., et al. Increased levels of adipokines in bipolar disorder. J. Psychiatr. Res. 2012, 46:389-393.
5. Berk M., Berk L., Dodd S., Cotton S., Macneil C., Daglas R., et al. Stage managing bipolar disorder. Bipolar Disord. 2014, 16:471-477.
6. Berk M., Kapczinski F., Andreazza A.C., Dean O.M., Giorlando F., Maes M., et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav. Rev. 2011, 35:804-817.
7. Bluher M., Mantzoros C.S. From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. Metabolism 2015, 64:131-145.
8. Bluher M., Rudich A., Kloting N., Golan R., Henkin Y., Rubin E., et al. Two patterns of adipokine and other biomarker dynamics in a long-term weight loss intervention. Diabetes Care 2012, 35:342-349.
9. Bly M.J., Taylor S.F., Dalack G., Pop-Busui R., Burghardt K.J., Evans S.J., et al. Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population. Bipolar Disord. 2014, 16:277-288.
10. Brietzke E., Kapczinski F., Grassi-Oliveira R., Grande I., Vieta E., McIntyre R.S. Insulin dysfunction and allostatic load in bipolar disorder. Expert Rev. Neurother. 2011, 11:1017-1028.
11. Calkin C., van de Velde C., Ruzickova M., Slaney C., Garnham J., Hajek T., et al. Can body mass index help predict outcome in patients with bipolar disorder?. Bipolar Disord. 2009, 11:650-656.
12. Calkin C.V., Gardner D.M., Ransom T., Alda M. The relationship between bipolar disorder and type 2 diabetes: more than just co-morbid disorders. Ann. Med. 2013, 45:171-181.
13. Calkin C.V., Ruzickova M., Uher R., Hajek T., Slaney C.M., Garnham J.S., et al. Insulin resistance and outcome in bipolar disorder. Br. J. Psychiatry 2015, 206:52-57.
14. Christou G.A., Kiortsis D.N. Adiponectin and lipoprotein metabolism. Obes. Rev. 2013, 14:939-949.
15. Chwastiak L.A., Rosenheck R.A., Kazis L.E. Association of psychiatric illness and obesity, physical inactivity, and smoking among a national sample of veterans. Psychosomatics 2011, 52:230-236.
16. Correll C.U., Detraux J., De Lepeleire J., De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 2015, 14:119-136.
17. Crump C., Sundquist K., Winkleby M.A., Sundquist J. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. JAMA Psychiatry 2013 Sep, 70(9):931-939. 10.1001/jamapsychiatry.2013.1394.
18. Czepielewski L., Daruy-Filho L., Brietzke E., Grassi-Oliveira R. Bipolar disorder and metabolic syndrome: a systematic review. Rev. Bras. Psiquiatr. 2013 Mar, 35(1):88-93.
19. Dakwar E., Blanco C., Lin K.H., Liu S.M., Warden D., Trivedi M., et al. Exercise and mental illness: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). J. Clin. Psychiatry 2012, 73:960-966.
20. Davison K.M., Kaplan B.J. Food intake and blood cholesterol levels of community-based adults with mood disorders. BMC Psychiatry 2012, 12:10.
21. Despres J.P. Health consequences of visceral obesity. Ann. Med. 2001, 33:534-541.
22. Elmslie J.L., Porter R.J., Joyce P.R., Hunt P.J., Shand B.I., Scott R.S. Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls. Aust. N. Z. J. Psychiatry 2009, 43:53-60.
23. Esmaili S., Xu A., George J. The multifaceted and controversial immunometabolic actions of adiponectin. Trends Endocrinol. Metab. 2014, 25:444-451.
24. Evans S.J., Ringrose R.N., Harrington G.J., Mancuso P., Burant C.F., McInnis M.G. Dietary intake and plasma metabolomic analysis of polyunsaturated fatty acids in bipolar subjects reveal dysregulation of linoleic acid metabolism. J. Psychiatr. Res. 2014, 57:58-64.
25. Fagiolini A., Frank E., Scott J.A., Turkin S., Kupfer D.J. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord. 2005, 7:424-430.
26. Field A.E., Camargo C.A., Ogino S. The merits of subtyping obesity: one size does not fit all. JAMA 2013, 310:2147-2148.
27. Fries G.R., Vasconcelos-Moreno M.P., Gubert C., dos Santos B.T., Sartori J., Eisele B., et al. Hypothalamic-pituitary-adrenal axis dysfunction and illness progression in bipolar disorder. Int. J. Neuropsychopharmacol. 2014, 18.
28. Gama C.S., Kunz M., Magalhaes P.V., Kapczinski F. Staging and neuroprogression in bipolar disorder: a systematic review of the literature. Rev. Bras. Psiquiatr. 2013, 35:70-74.
29. Goldstein B.I., Liu S.M., Schaffer A., Sala R., Blanco C. Obesity and the three-year longitudinal course of bipolar disorder. Bipolar Disord. 2013, 15:284-293.
30. Goldstein B.I., Liu S.M., Zivkovic N., Schaffer A., Chien L.C., Blanco C. The burden of obesity among adults with bipolar disorder in the United States. Bipolar Disord. 2011, 13:387-395.
31. Gomes F.A., Almeida K.M., Magalhaes P.V., Caetano S.C., Kauer-Sant'Anna M., Lafer B., et al. Cardiovascular risk factors in outpatients with bipolar disorder: a report from the Brazilian Research Network in Bipolar Disorder. Rev. Bras. Psiquiatr. 2013, 35:126-130.
32. Henderson D.C., Vincenzi B., Andrea N.V., Ulloa M., Copeland P.M. Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiatry 2015, 2:452-464.
33. Hung Y.J., Hsieh C.H., Chen Y.J., Pei D., Kuo S.W., Shen D.C., et al. Insulin sensitivity, proinflammatory markers and adiponectin in young males with different subtypes of depressive disorder. Clin. Endocrinol. (Oxf.) 2007, 67:784-789.
34. Kapczinski F., Magalhaes P.V., Balanza-Martinez V., Dias V.V., Frangou S., Gama C.S., et al. Staging systems in bipolar disorder: an International Society for Bipolar Disorders Task Force Report. Acta Psychiatr. Scand. 2014, 130:354-363.
35. Kapczinski F., Vieta E., Andreazza A.C., Frey B.N., Gomes F.A., Tramontina J., et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci. Biobehav. Rev. 2008, 32:675-692.
36. Katsuki A., Sumida Y., Gabazza E.C., Murashima S., Furuta M., Araki-Sasaki R., et al. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care 2001, 24:362-365.
37. Kemp D.E., Gao K., Chan P.K., Ganocy S.J., Findling R.L., Calabrese J.R. Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome. Bipolar Disord. 2010, 12:404-413.
38. Kemp D.E., Sylvia L.G., Calabrese J.R., Nierenberg A.A., Thase M.E., Reilly-Harrington N.A., et al. General medical burden in bipolar disorder: findings from the LiTMUS comparative effectiveness trial. Acta Psychiatr. Scand. 2014, 129:24-34.
39. Ko B.J., Park K.H., Mantzoros C.S. Diet patterns, adipokines, and metabolism: where are we and what is next?. Metabolism 2014, 63:168-177.
40. Kubota N., Yano W., Kubota T., Yamauchi T., Itoh S., Kumagai H., et al. Adiponectin stimulates AMP-activated protein kinase in the hypothalamus and increases food intake. Cell Metab. 2007, 6:55-68.
41. Kurt E., Guler O., Serteser M., Cansel N., Ozbulut O., Altinbas K., et al. The effects of electroconvulsive therapy on ghrelin, leptin and cholesterol levels in patients with mood disorders. Neurosci. Lett. 2007, 426:49-53.
42. Lackner N., Mangge H., Reininghaus E.Z., McIntyre R.S., Bengesser S.A., Birner A., et al. Body fat distribution and associations with metabolic and clinical characteristics in bipolar individuals. Eur. Arch. Psychiatry Clin. Neurosci. 2015, 265:313-319.
43. Lee H.J., Kim S.H., Kim E.Y., Lee N.Y., Yu H.Y., Kim Y.S., et al. Leptin is associated with mood status and metabolic homeostasis in patients with bipolar disorder. Neuropsychobiology 2014, 70:203-209.
44. Lee S.S., Kang S. Effects of regular exercise on obesity and type 2 diabete mellitus in Korean children: improvements glycemic control and serum adipokines level. J. Phys. Ther. Sci. 2015, 27:1903-1907.
45. Li Y., Qin G., Liu J., Mao L., Zhang Z., Shang J. Adipose tissue regulates hepatic cholesterol metabolism via adiponectin. Life Sci. 2014, 118:27-33.
46. Liu J., Guo M., Zhang D., Cheng S.Y., Liu M., Ding J., et al. Adiponectin is critical in determining susceptibility to depressive behaviors and has antidepressant-like activity. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:12248-12253.
47. Magalhaes P.V., Kapczinski F., Nierenberg A.A., Deckersbach T., Weisinger D., Dodd S., et al. Illness burden and medical comorbidity in the Systematic Treatment Enhancement Program for Bipolar Disorder. Acta Psychiatr. Scand. 2012, 125:303-308.
48. Mansur R.B., Brietzke E., McIntyre R.S. Is there a "metabolic-mood syndrome"? A review of the relationship between obesity and mood disorders. Neurosci. Biobehav. Rev. 2015, 52:89-104.
49. McEwen B.S. Mood disorders and allostatic load. Biol. Psychiatry 2003, 54:200-207.
50. McIntyre R.S., Danilewitz M., Liauw S.S., Kemp D.E., Nguyen H.T., Kahn L.S., et al. Bipolar disorder and metabolic syndrome: an international perspective. J. Affect Disord. 2010, 126:366-387.
51. McIntyre R.S., Muzina D.J., Kemp D.E., Blank D., Woldeyohannes H.O., Lofchy J., et al. Bipolar disorder and suicide: research synthesis and clinical translation. Curr. Psychiatry Rep. 2008, 10:66-72.
52. Munkholm K., Vinberg M., Kessing L.V. Peripheral blood brain-derived neurotrophic factor in bipolar disorder: a comprehensive systematic review and meta-analysis. Mol. Psychiatry 2015.
53. Naukkarinen J., Rissanen A., Kaprio J., Pietilainen K.H. Causes and consequences of obesity: the contribution of recent twin studies. Int. J. Obes. (Lond.) 2012, 36:1017-1024.
54. Nicolas S., Veyssiere J., Gandin C., Zsurger N., Pietri M., Heurteaux C., et al. Neurogenesis-independent antidepressant-like effects of enriched environment is dependent on adiponectin. Psychoneuroendocrinology 2015, 57:72-83.
55. Nishimura M., Izumiya Y., Higuchi A., Shibata R., Qiu J., Kudo C., et al. Adiponectin prevents cerebral ischemic injury through endothelial nitric oxide synthase dependent mechanisms. Circulation 2008, 117:216-223.
56. Ouchi N., Parker J.L., Lugus J.J., Walsh K. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 2011, 11:85-97.
57. Panizzutti B., Gubert C., Schuh A.L., Ferrari P., Bristot G., Fries G.R., et al. Increased serum levels of eotaxin/CCL11 in late-stage patients with bipolar disorder: an accelerated aging biomarker?. J. Affect Disord. 2015, 182:64-69.
58. Pena R., Marquina D., Serrano A., Elfakih Y., de Baptista E.A., Carrizo E., et al. Frequency of abnormal correlation between leptin and the body mass index during first and second generation antipsychotic drug treatment. Schizophr. Res. 2008, 106:315-319.
59. Perugi G., Quaranta G., Belletti S., Casalini F., Mosti N., Toni C., et al. General medical conditions in 347 bipolar disorder patients: clinical correlates of metabolic and autoimmune-allergic diseases. J. Affect Disord. 2015, 170:95-103.
60. Qi Y., Takahashi N., Hileman S.M., Patel H.R., Berg A.H., Pajvani U.B., et al. Adiponectin acts in the brain to decrease body weight. Nat. Med. 2004, 10:524-529.
61. Reininghaus E.Z., McIntyre R.S., Reininghaus B., Geisler S., Bengesser S.A., Lackner N., et al. Tryptophan breakdown is increased in euthymic overweight individuals with bipolar disorder: a preliminary report. Bipolar Disord. 2014, 16:432-440.
62. Ruzickova M., Slaney C., Garnham J., Alda M. Clinical features of bipolar disorder with and without comorbid diabetes mellitus. Can. J. Psychiatry 2003, 48:458-461.
63. Schneider M.R., DelBello M.P., McNamara R.K., Strakowski S.M., Adler C.M. Neuroprogression in bipolar disorder. Bipolar Disord. 2012, 14:356-374.
64. Schulkin J. Allostasis: a neural behavioral perspective. Horm. Behav. 2003, 43:21-27. discussion 8-30.
65. Sicras A., Rejas J., Navarro R., Serrat J., Blanca M. Metabolic syndrome in bipolar disorder: a cross-sectional assessment of a Health Management Organization database. Bipolar Disord. 2008, 10:607-616.
66. Soeiro-de-Souza M.G., Gold P.W., Brunoni A.R., de Sousa R.T., Zanetti M.V., Carvalho A.F., et al. Lithium decreases plasma adiponectin levels in bipolar depression. Neurosci. Lett. 2014, 564:111-114.
67. Spranger J., Verma S., Gohring I., Bobbert T., Seifert J., Sindler A.L., et al. Adiponectin does not cross the blood-brain barrier but modifies cytokine expression of brain endothelial cells. Diabetes 2006, 55:141-147.
68. Sterling P. Allostasis: a model of predictive regulation. Physiol. Behav. 2012, 106:5-15.
69. Tsai S.Y., Lee H.C., Chen C.C. Hyperinsulinaemia associated with beta-adrenoceptor antagonist in medicated bipolar patients during manic episode. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:1038-1043.
70. Vancampfort D., Vansteelandt K., Correll C.U., Mitchell A.J., De Herdt A., Sienaert P., et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am. J. Psychiatry 2013, 170:265-274.
71. Wallace T.M., Levy J.C., Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care 2004, 27:1487-1495.